|Articles|September 25, 2016
Tufts CSDD Releases Findings from Diabetes Study
September 26, 2016
Advertisement
According to results of a new study by the Tufts Center for the Study of Drug Development, the development process for new diabetes and non-diabetes endocrine drugs is riskier compared to all drug development. The study examined the development pathways and characteristics of 27 diabetes and 34 non-diabetes endocrine drugs.
Read the full release
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly Releases Updated Safety Data for Foundayo Following FDA’s Request
2
Johnson & Johnson’s Experience Navigating The Commissioner’s National Priority Voucher Program
3
How AI Is Transforming Drug Labeling
4
FDA’s Shift Signals a New Era for Data-Driven Drug Development
5